The Unmet Need

WHO Group 2 : Pulmonary Hypertension with Left Heart Disease

As PH-HFpEF has as an essential feature an elevation of the pulmonary capillary wedge pressure (PCWP), shortness of breath and reduced exercise capacity are the predominant symptoms and can be quite severe.  Patients with PH-HFpEF also have a poor quality of life, and an estimated 5-year survival of only ~50%.  This is similar to the current estimated 5-year survival of PAH.

Despite the large population of PH-HFpEF patients, there are no effective treatments.Most patients are prescribed diuretics which have limited effectiveness.The pulmonary vasodilator therapies approved for the treatment of Group I (PAH) patients have all been investigated for the treatment of PH-HFpEF, and none have shown to be effective.

Given that PH-HFpEF is the most common form of pulmonary hypertension with very poor outcomes and no available effective therapies, it is a condition with a very high unmet medical need.